At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCAX Bicara Therapeutics
Post-Mkt 10-05 17:25:28 EDT
17.29
-0.34
-1.93%
盘后18.14
+0.85+4.92%
17:04 EDT
High19.12Low17.13Vol640.75K
Open17.63D1 Closing17.63Amplitude11.29%
Mkt Cap1.14BTradable Cap635.62MTotal Shares66.17M
T/O11.11MT/O Rate1.74%Tradable Shares36.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Bicara Therapeutics Grants New Hires Stock Options for 207,150 Shares at $18.20 Each
Reuters  ·  10-05 20:32
Bicara Therapeutics Grants New Hires Stock Options for 207,150 Shares at $18.20 Each
Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-05 20:30
Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  10-05 20:30
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics President, COO and Interim CEO Ryan Cohlhepp Disposes of Common Shares Worth $400,049.15
Reuters  ·  09-11
Bicara Therapeutics President, COO and Interim CEO Ryan Cohlhepp Disposes of Common Shares Worth $400,049.15
Bicara Therapeutics: Buy Rating Reiterated on FICERA’s Survival Benefit in Difficult HNSCC Segment, Price Target Maintained at $30
TIPRANKS  ·  09-08
Bicara Therapeutics: Buy Rating Reiterated on FICERA’s Survival Benefit in Difficult HNSCC Segment, Price Target Maintained at $30
Bicara Therapeutics Issues Inducement Stock Options for 380,575 Shares at $23.42 Each
Reuters  ·  09-03
Bicara Therapeutics Issues Inducement Stock Options for 380,575 Shares at $23.42 Each
Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-03
Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  09-03
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Secures Boston Headquarters Through Sublease
TIPRANKS  ·  08-26
Bicara Therapeutics Secures Boston Headquarters Through Sublease
How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors
Simply Wall St.  ·  08-24
How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf Filing - Has The Bull Case Changed?
Simply Wall St.  ·  08-16
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf Filing - Has The Bull Case Changed?
Bicara Therapeutics CFO Jennifer Larson Files Initial Beneficial Ownership Statement
Reuters  ·  08-15
Bicara Therapeutics CFO Jennifer Larson Files Initial Beneficial Ownership Statement
Bicara Awards CFO Jennifer Larson Stock Option for 285,000 Shares at $24.63 Each
Reuters  ·  08-14
Bicara Awards CFO Jennifer Larson Stock Option for 285,000 Shares at $24.63 Each
Bicara Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  08-14
Bicara Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-14
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
TIPRANKS  ·  08-13
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
TIPRANKS  ·  08-13
Mizuho Securities Reaffirms Their Hold Rating on Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics CFO Ivan Hyep Disposes of $349,591 in Common Shares
Reuters  ·  08-13
Bicara Therapeutics CFO Ivan Hyep Disposes of $349,591 in Common Shares
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Benzinga Earnings  ·  08-12
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics is Maintained at Buy by BTIG
Dow Jones  ·  08-12
Bicara Therapeutics is Maintained at Buy by BTIG

Introduction

Company Name.
Bicara Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Bicara Therapeutics Inc. was incorporated under Delaware law on December 12, 2018. The company is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, simultaneously targets the EGFR and TGF-β pathways and is currently being evaluated in a pivotal trial for head and neck squamous cell carcinoma.
Issue price:
--